Quiet on the insider front: nobody at IO Biotech, Inc. bought or sold IOBT shares at market prices this past year.
No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
Quiet on the insider front: nobody at IO Biotech, Inc. bought or sold IOBT shares at market prices this past year.
No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jun 2, 2025 | Hunter Heidi | Director | Buy | 15,000 | $1.39 | $21K | SEC |
| Dec 26, 2024 | Ahmad Qasim Iftikhar | Executive Officer | Buy | 31,350 | $0.85 | $27K | SEC |
| Dec 23, 2024 | Zocca Mai-Britt | CEO | Buy | 12,500 | $0.81 | $10K | SEC |
| Dec 23, 2024 | Sullivan Amy | CFO | Buy | 10,250 | $0.83 | $9K | SEC |
| Dec 23, 2024 | Smith Devin Whittemore | Executive Officer | Buy | 12,000 | $0.81 | $10K | SEC |
| Jul 26, 2024 | Novo Holdings A/S | 10% Owner | Sell | 51,522 | $1.33 | $69K | SEC |
| Jul 26, 2024 | Novo Holdings A/S | 10% Owner | Sell | 23,478 | $1.31 | $31K | SEC |
| May 14, 2024 | Novo Holdings A/S | 10% Owner | Sell | 658,809 | $1.22 | $804K | SEC |
| Feb 13, 2024 | Novo Holdings A/S | 10% Owner | Sell | 658,809 | $1.50 | $988K | SEC |
| Nov 24, 2023 | Burkavage Brian | Executive Officer | Buy | 5,000 | $0.99 | $5K | SEC |
| Nov 24, 2023 | Burkavage Brian | Executive Officer | Buy | 5,000 | $1.04 | $5K | SEC |
| Aug 11, 2023 | Novo Holdings A/S | 10% Owner | Buy | 2,469,135 | $2.03 | $5.0M | SEC |
| Aug 10, 2023 | Vivo Capital IX, LLC | 10% Owner | Buy | 3,157,894 | $1.90 | $6.0M | SEC |
| Mar 20, 2023 | Sullivan Amy | CFO | Buy | 25,000 | $2.32 | $58K | SEC |
There were no open-market insider trades in IOBT in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
No congressional trades in IOBT were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).